Qiagen N.V [QGEN] vs Idexx Laboratories [IDXX] Detailed Stock Comparison
Qiagen N.V
NYSE
Loading...
Idexx Laboratories
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Qiagen N.V wins in 8 metrics, Idexx Laboratories wins in 11 metrics, with 0 ties. Idexx Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Qiagen N.V | Idexx Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 111.09 | 54.48 | Idexx Laboratories |
| Price-to-Book Ratio | 2.95 | 36.01 | Qiagen N.V |
| Debt-to-Equity Ratio | 41.19 | 84.81 | Qiagen N.V |
| PEG Ratio | 20.86 | 54.80 | Qiagen N.V |
| EV/EBITDA | 10.72 | 38.11 | Qiagen N.V |
| Profit Margin (TTM) | 18.30% | 24.41% | Idexx Laboratories |
| Operating Margin (TTM) | 27.06% | 33.62% | Idexx Laboratories |
| EBITDA Margin (TTM) | 27.06% | 33.62% | Idexx Laboratories |
| Return on Equity | 10.81% | 64.87% | Idexx Laboratories |
| Return on Assets (TTM) | 9.10% | 23.26% | Idexx Laboratories |
| Free Cash Flow (TTM) | $502.31M | $798.08M | Idexx Laboratories |
| 1-Year Return | 5.72% | 36.29% | Idexx Laboratories |
| Price-to-Sales Ratio (TTM) | 5.07 | 12.99 | Qiagen N.V |
| Enterprise Value | $10.79B | $53.08B | Idexx Laboratories |
| EV/Revenue Ratio | 5.29 | 13.15 | Qiagen N.V |
| Gross Profit Margin (TTM) | 63.85% | 62.62% | Qiagen N.V |
| Revenue per Share (TTM) | $9 | $50 | Idexx Laboratories |
| Earnings per Share (Diluted) | $0.43 | $12.03 | Idexx Laboratories |
| Beta (Stock Volatility) | 0.64 | 1.50 | Qiagen N.V |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Qiagen N.V vs Idexx Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Qiagen N.V | -0.66% | -3.80% | 0.40% | 13.95% | 19.86% | 7.91% |
| Idexx Laboratories | 1.23% | 22.88% | 22.13% | 34.30% | 41.55% | 60.95% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Qiagen N.V | 5.72% | -3.81% | -2.89% | 66.50% | 154.48% | 266.84% |
| Idexx Laboratories | 36.29% | 66.00% | 73.45% | 747.91% | 2,238.52% | 4,129.18% |
Performance & Financial Health Analysis: Qiagen N.V vs Idexx Laboratories
| Metric | QGEN | IDXX |
|---|---|---|
| Market Information | ||
| Market Cap | $10.34B | $52.43B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,420,977 | 1,088,184 |
| 90 Day Avg. Volume | 1,496,859 | 682,031 |
| Last Close | $48.04 | $658.06 |
| 52 Week Range | $37.63 - $51.88 | $356.14 - $688.12 |
| % from 52W High | -7.40% | -4.37% |
| All-Time High | $60.81 (Jul 17, 2000) | $706.95 (Jul 26, 2021) |
| % from All-Time High | -21.00% | -6.92% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.11% |
| Quarterly Earnings Growth | 0.05% | 0.45% |
| Financial Health | ||
| Profit Margin (TTM) | 0.18% | 0.24% |
| Operating Margin (TTM) | 0.27% | 0.34% |
| Return on Equity (TTM) | 0.11% | 0.65% |
| Debt to Equity (MRQ) | 41.19 | 84.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $16.17 | $18.20 |
| Cash per Share (MRQ) | $4.40 | $2.06 |
| Operating Cash Flow (TTM) | $675.03M | $905.81M |
| Levered Free Cash Flow (TTM) | $716.23M | $625.74M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Qiagen N.V vs Idexx Laboratories
| Metric | QGEN | IDXX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 111.09 | 54.48 |
| Forward P/E | 20.86 | 54.80 |
| PEG Ratio | 20.86 | 54.80 |
| Price to Sales (TTM) | 5.07 | 12.99 |
| Price to Book (MRQ) | 2.95 | 36.01 |
| Market Capitalization | ||
| Market Capitalization | $10.34B | $52.43B |
| Enterprise Value | $10.79B | $53.08B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.29 | 13.15 |
| Enterprise to EBITDA | 10.72 | 38.11 |
| Risk & Other Metrics | ||
| Beta | 0.64 | 1.50 |
| Book Value per Share (MRQ) | $16.17 | $18.20 |
Financial Statements Comparison: Qiagen N.V vs Idexx Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | QGEN | IDXX |
|---|---|---|
| Revenue/Sales | $483.46M | $998.43M |
| Cost of Goods Sold | $174.78M | $375.05M |
| Gross Profit | $308.68M | $623.38M |
| Research & Development | $43.78M | $59.06M |
| Operating Income (EBIT) | $125.16M | $316.53M |
| EBITDA | $184.37M | $351.81M |
| Pre-Tax Income | $119.55M | $310.08M |
| Income Tax | $28.79M | $67.41M |
| Net Income (Profit) | $90.76M | $242.68M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | QGEN | IDXX |
|---|---|---|
| Cash & Equivalents | $638.76M | $163.97M |
| Total Current Assets | $1.74B | $1.32B |
| Total Current Liabilities | $516.94M | $1.14B |
| Long-Term Debt | $1.35B | $546.80M |
| Total Shareholders Equity | $3.41B | $1.45B |
| Retained Earnings | $2.50B | $5.58B |
| Property, Plant & Equipment | N/A | $833.62M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | QGEN | IDXX |
|---|---|---|
| Operating Cash Flow | $190.30M | $235.07M |
| Capital Expenditures | $-43.90M | $-30.03M |
| Free Cash Flow | $95.48M | $207.94M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-400.89M |
Short Interest & Institutional Ownership Analysis
| Metric | QGEN | IDXX |
|---|---|---|
| Shares Short | 6.30M | 2.64M |
| Short Ratio | 4.40 | 5.58 |
| Short % of Float | 0.04% | 0.04% |
| Average Daily Volume (10 Day) | 1,420,977 | 1,088,184 |
| Average Daily Volume (90 Day) | 1,496,859 | 682,031 |
| Shares Outstanding | 216.12M | 81.60M |
| Float Shares | 214.77M | 79.14M |
| % Held by Insiders | 0.02% | 0.01% |
| % Held by Institutions | 0.87% | 1.00% |
Dividend Analysis & Yield Comparison: Qiagen N.V vs Idexx Laboratories
| Metric | QGEN | IDXX |
|---|---|---|
| Last 12-Month Dividend | $0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $0.44 | N/A |
| 3-Year Avg Dividend Yield | 3.03% | N/A |
| 3-Year Total Dividends | $1.32 | N/A |
| Ex-Dividend Date | Jan 30, 2024 | N/A |